Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)

Scientific paper - Original scientific paper

• Author: Maja Sirotković-Skerlev
• Author: Natalija Dedić Plavetić
• Author: Filip Sedlić
• Author: Sanja Kusačić Kuna
• Author: Damir Vrbanec
• Author: Borislav Belev
• Author: Stjepko Pleština
• Author: Zdenko Kovač
• Author: Ana Kulić
• Author's institution: University of Zagreb; School of Medicine; (Department of Pathophysiology)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Pathophysiology

Abstract (english)

BACKGROUND: Apoptosis inhibition is a major tumorigenic factor. Bcl-2 dysregulation and TP53 mutation status, which may correlate with autoantibody generation, contribute to impaired apoptosis. ----- OBJECTIVE: This study aimed to investigate the prognostic value of circulating Bcl-2 and anti-p53 antibodies (p53Abs) in a 17.5-year follow-up of breast cancer patients. We also analysed the correlations of Bcl-2 and p53Abs with various clinicopathological parameters in order to assess their impact on tumor aggressiveness. ----- METHODS: Serum Bcl-2 and p53Abs levels were analysed by the enzyme-linked immunosorbent assay (ELISA) in 82 patients with invasive breast cancer and twenty individuals without malignancy. ----- RESULTS: Serum Bcl-2 and p53Abs levels in breast cancer patients were significantly higher than those in controls. Patients with high levels of Bcl-2 (cut-off 200 U/ml) had a poorer prognosis (17.5-year survival) than those with lower Bcl-2 values. In combined analysis the subgroup of patients with elevated p53Abs (cut-off 15 U/ml) and elevated Bcl-2 (cut-offs 124 U/ml and 200 U/ml) had the worse prognosis in 17.5-year survival. In correlation analysis p53Abs and Bcl-2 were associated with unfavorable clinicopathological parameters. ----- CONCLUSIONS: Our results suggest that breast cancer patients with high serum levels of p53Abs and Bcl-2 present an especially unfavorable group in a long follow-up.

• Keywords (english): Bcl-2; Breast cancer; ELISA; anti-p53 antibodies; survival
• Language: english
• Publication type: Scientific paper - Original scientific paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Accepted version
• Journal title: Cancer Biomarkers
• Numbering: vol. 30, no. 1, pp. 95-104
• p-ISSN: 1574-0153
• e-ISSN: 1875-8592
• DOI: https://doi.org/10.3233/CBM-201497
• URN:NBN: urn:nbn:hr:105:834430
• Publication: 2021
• Document URL: https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/CBM-201497
• Type of resource: Text
• Access conditions: Open access
• Created on: 2021-04-21 14:34:32